Bard/Genyx
This article was originally published in The Gray Sheet
Executive Summary
C.R. Bard acquires privately held Genyx Medical, developer of Uryx injectable bulking agent used to treat female stress urinary incontinence. Genyx plans to submit a PMA for Uryx to FDA by June. When the liquid polymer is injected into the area encompassing the urethra, it becomes a spongy mass and lends support to the urinary sphincter, limiting or stopping the accidental loss of urine. Bard currently manufacturers Contigen, a competing product...